Agios Pharmaceuticals (FRA:8AP) Short Interest


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
44 GF Score
Price €32.00
GF Value €70.71
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:8AP vs CAPR, SNDX, SLS: Short Interest Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agios Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Short Interest falls into.


FRA:8AP
44GF Score
Agios Pharmaceuticals Inc FRA:8AP
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €32.00 is trading 54.7% below its estimated GF Value™ of €70.71. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:8AP:

  • Short Interest:
  • GF Value™: €70.71 vs. price of €32.00 (54.7% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score

Get the complete analysis for FRA:8AP

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price
€70.71
GF Value